J.P. Morgan is out with its report today on C.R. Bard BCR, maintaining Neutral.
In a note to clients, J.P. Morgan writes, "We view Bard as an attractive mix of assets, with a sustainable longer term growth profile of 5-6% on the top line and 10-11% on the bottom line. From this base rate, we see upside potential for Bard from acquisitions or should healthcare volumes and/or device utilization levels improve in the quarters ahead."
J.P. Morgan maintains a $104 PT on BCR.
At the time of posting, shares of BCR were trading pre-market at $105.86, down 6.08% from Thursday's close.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in